
Breast discharge and, on rare occasions, ectopic pregnancies have been reported with the use of Cerazette during post-marketing surveillance (see Precautions). In addition, hypersensitivity reactions (including angioedema and anaphylaxis) have been reported during post-marketing surveillance.
In women using (combined) oral contraceptives a number of (serious) undesirable effects have been reported. These include venous thromboembolic disorders, arterial thromboembolic disorders, hormone-dependent tumours (e.g., breast cancer), and chloasma, some of which are discussed in more detail in Precautions.
View ADR Reporting Link